Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Basic Research

Inhibitory member of the apoptosis-stimulating protein of p53 (ASPP) family promotes growth and tumorigenesis in human p53-deficient prostate cancer cells

Prostate Cancer and Prostatic Diseases volume 14, pages 219–224 (2011)Cite this article

Subjects

Abstract

iASPP is a member of the apoptosis-stimulating protein of p53 (ASPP) family and an evolutionarily conserved inhibitor of p53. Higher levels of iASPP proteins were examined in paraffin-embedded sections collected from 30 patients with prostate cancer using an immunohistochemical method. We found that specially knocking down iASPP with lentivirus-mediated small interfering RNA inhibited the growth, in vitro colony-forming capacity and in vivo tumorigenesis of p53-defective prostate cancer cells. Importantly, inhibition of iASPP induced cell apoptosis, which confers the inhibitory effect on cell survival. We conclude that iASPP is essential for prostate cancer cellular proliferation and survival and may be a potential target for the gene therapy for prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.

    Article  PubMed  Google Scholar 

  2. Parkin DM, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108.

    Article  PubMed  Google Scholar 

  3. Vousden KH, Lane DP . p53 in health and disease. Nat Rev Mol Cell Bio 2007; 8: 275–283.

    Article  CAS  Google Scholar 

  4. Sullivan A, Lu X . ASPP: a new family of oncogenes and tumour suppressor genes. Brit J Cancer 2007; 96: 196–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Samuels-Lev Y, O’Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8: 781–794.

    Article  CAS  PubMed  Google Scholar 

  6. Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X . ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol 2004; 24: 1341–1350.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bell HS, Ryan KM . iASPP inhibition. increased options in targeting the p53 family for cancer therapy. Cancer Res 2008; 68: 4959–4962.

    Article  CAS  PubMed  Google Scholar 

  8. Bergamaschi D, Samuels Y, O’Neil NJ, Trigiante G, Crook T, Hsieh JK et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 2003; 33: 162–167.

    Article  CAS  PubMed  Google Scholar 

  9. Gao X, Xin HM, Lu X, Zhong S, Gu SZ, Chen J . Effect of RNA interference of iASPP on the apoptosis in MCF-7 breast cancer cells. Cancer Invest 2008; 26: 878–882.

    Article  PubMed  Google Scholar 

  10. Agarwal MK, Hastak K, Jackson MW, Breit SN, Stark GR, Agarwal ML . Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in S phase in response to starvation for DNA precursors. Proc Natl Acad Sci USA 2006; 103: 16278–16283.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mohapatra S, Chu B, Zhao X, Pledger WJ . Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res 2005; 65: 7717–7723.

    Article  CAS  PubMed  Google Scholar 

  12. Gurova KV, Rokhlin OW, Budanov AV, Burdelya LG, Chumakov PM, Cohen MB et al. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res 2003; 63: 2905–2912.

    CAS  PubMed  Google Scholar 

  13. Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 2005; 11: 5084–5089.

    Article  CAS  PubMed  Google Scholar 

  14. Arocho A, Chen B, Ladanyi M, Pan Q . Validation of the 2-[DELTA][DELTA]Ct calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts. Diagnostic Mol Pathol 2006; 15: 56–61.

    Article  CAS  Google Scholar 

  15. Xu Y, Wang Z, Wang J, Li J, Wang H, Yue W . Lentivirus-mediated knockdown of cyclin Y (CCNY) inhibits glioma cell proliferation. Oncol Res 2010; 18: 359–364.

    Article  PubMed  Google Scholar 

  16. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067–1070.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Sinn PL, Sauter SL, McCray PB . Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther 2005; 12: 1089–1098.

    Article  CAS  PubMed  Google Scholar 

  18. Wang YH, Wang ZX, Qiu Y, Xiong J, Chen YX, Miao DS et al. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells. Mol Cell Biochem 2009; 327: 257–266.

    Article  CAS  PubMed  Google Scholar 

  19. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M et al. Specific loss of apoptotic but not cell-cycle arrest function in a human tumour derived p53 mutant. EMBO J 1996; 15: 827–838.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Bell HS, Ryan KM . iASPP inhibition. increased options in targeting the p53 family for cancer therapy. Cancer Res 2008; 68: 4959–4962.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. B Zhang and H J Xiao: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Infertility and Sexual Medicine, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

    B Zhang, J Chen, X Tao & L H Cai

  2. Department of Urology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

    H J Xiao

Authors
  1. B Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H J Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. X Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L H Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Chen.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, B., Xiao, H., Chen, J. et al. Inhibitory member of the apoptosis-stimulating protein of p53 (ASPP) family promotes growth and tumorigenesis in human p53-deficient prostate cancer cells. Prostate Cancer Prostatic Dis 14, 219–224 (2011). https://doi.org/10.1038/pcan.2011.25

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2011.25

Keywords

This article is cited by

Search

Advanced search

Quick links